Ribo Life Science Buys Back 200 H Shares, Lifting Treasury Stock to 972,200 Units

Bulletin Express10-21

On 21 October 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) executed an on-market repurchase of 200 H shares at a uniform price of HK$52.25 per share. The transaction totalled HK$10,450.

Following the buyback, the company’s issued share capital (excluding treasury shares) decreased marginally to 169.58 million shares, down from 169.58 million previously—an immaterial reduction of 0.0001%. Treasury shares rose to 972,200, bringing total shares in issue (including treasury stock) to 170.55 million.

The repurchase was conducted under the mandate approved by shareholders on 5 June 2026, which authorises the company to repurchase up to 17.06 million shares. Cumulative repurchases under this mandate now stand at 972,200 shares, representing 0.57% of the shares outstanding on the mandate date, leaving over 16 million shares—about 94% of the authorisation—still available.

All regulatory requirements of the Hong Kong Stock Exchange’s Main Board Rules were observed, and a 30-day moratorium on new share issues or treasury-share disposals remains in place until 20 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment